96 related articles for article (PubMed ID: 24791863)
1. Interleukin-32, not reduced by salmeterol/fluticasone propionate in smokers with chronic obstructive pulmonary disease.
Du Y; Wang W; Yang W; He B
Chin Med J (Engl); 2014; 127(9):1613-8. PubMed ID: 24791863
[TBL] [Abstract][Full Text] [Related]
2. Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease.
Barnes NC; Qiu YS; Pavord ID; Parker D; Davis PA; Zhu J; Johnson M; Thomson NC; Jeffery PK;
Am J Respir Crit Care Med; 2006 Apr; 173(7):736-43. PubMed ID: 16424444
[TBL] [Abstract][Full Text] [Related]
3. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.
Calverley PM; Anderson JA; Celli B; Ferguson GT; Jenkins C; Jones PW; Yates JC; Vestbo J;
N Engl J Med; 2007 Feb; 356(8):775-89. PubMed ID: 17314337
[TBL] [Abstract][Full Text] [Related]
4. Anti-inflammatory effects of salmeterol/fluticasone, tiotropium/fluticasone or tiotropium in COPD.
Perng DW; Tao CW; Su KC; Tsai CC; Liu LY; Lee YC
Eur Respir J; 2009 Apr; 33(4):778-84. PubMed ID: 19129278
[TBL] [Abstract][Full Text] [Related]
5. The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease.
Sin DD; Man SF; Marciniuk DD; Ford G; FitzGerald M; Wong E; York E; Mainra RR; Ramesh W; Melenka LS; Wilde E; Cowie RL; Williams D; Gan WQ; Rousseau R;
Am J Respir Crit Care Med; 2008 Jun; 177(11):1207-14. PubMed ID: 18310480
[TBL] [Abstract][Full Text] [Related]
6. Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease.
Vestbo J; Pauwels R; Anderson JA; Jones P; Calverley P;
Thorax; 2005 Apr; 60(4):301-4. PubMed ID: 15790985
[TBL] [Abstract][Full Text] [Related]
7. A double-blind crossover study comparing the safety and efficacy of three weeks of Flu/Sal 250/50 bid plus albuterol 180 ug prn q4 hours to Flu/Sal 250/50 bid plus albuterol/Ipratropium bromide 2 puffs prn q4 hours in patients with chronic obstructive pulmonary disease.
Balkissoon R; Make B
COPD; 2008 Aug; 5(4):221-7. PubMed ID: 18671147
[TBL] [Abstract][Full Text] [Related]
8. Changes in lung function and health status in patients with COPD treated with tiotropium or salmeterol plus fluticasone.
Kurashima K; Hara K; Yoneda K; Kanauchi T; Kagiyama N; Tokunaga D; Takayanagi N; Ubukata M; Sugita Y
Respirology; 2009 Mar; 14(2):239-44. PubMed ID: 19210650
[TBL] [Abstract][Full Text] [Related]
9. Effect on lung function and morning activities of budesonide/formoterol versus salmeterol/fluticasone in patients with COPD.
Partridge MR; Schuermann W; Beckman O; Persson T; Polanowski T
Ther Adv Respir Dis; 2009 Aug; 3(4):1-11. PubMed ID: 19734176
[TBL] [Abstract][Full Text] [Related]
10. Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial.
Wouters EF; Postma DS; Fokkens B; Hop WC; Prins J; Kuipers AF; Pasma HR; Hensing CA; Creutzberg EC;
Thorax; 2005 Jun; 60(6):480-7. PubMed ID: 15923248
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of salmeterol xinafoate plus fluticasone propionate for the treatment of chronic obstructive pulmonary disease.
Restrepo RD; Tate A; Coquat J
Expert Opin Pharmacother; 2013 Oct; 14(14):1993-2002. PubMed ID: 23898819
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease.
Mahler DA; Wire P; Horstman D; Chang CN; Yates J; Fischer T; Shah T
Am J Respir Crit Care Med; 2002 Oct; 166(8):1084-91. PubMed ID: 12379552
[TBL] [Abstract][Full Text] [Related]
13. Comparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD: a randomized controlled study.
Jung KS; Park HY; Park SY; Kim SK; Kim YK; Shim JJ; Moon HS; Lee KH; Yoo JH; Lee SD; ;
Respir Med; 2012 Mar; 106(3):382-9. PubMed ID: 21975275
[TBL] [Abstract][Full Text] [Related]
14. Comparison between the effects of generic and original salmeterol/fluticasone combination (SFC) treatment on airway inflammation in stable asthmatic patients.
Maneechotesuwan K; Assawabhumi J; Rattanasaengloet K; Suthamsmai T; Pipopsuthipaiboon S; Udompunturak S
J Med Assoc Thai; 2014 Mar; 97 Suppl 3():S91-100. PubMed ID: 24772585
[TBL] [Abstract][Full Text] [Related]
15. A comparison of the efficacy and safety of once-daily fluticasone furoate/vilanterol with twice-daily fluticasone propionate/salmeterol in moderate to very severe COPD.
Agustí A; de Teresa L; De Backer W; Zvarich MT; Locantore N; Barnes N; Bourbeau J; Crim C
Eur Respir J; 2014 Mar; 43(3):763-72. PubMed ID: 24114969
[TBL] [Abstract][Full Text] [Related]
16. Exhaled nitric oxide, systemic inflammation, and the spirometric response to inhaled fluticasone propionate in severe chronic obstructive pulmonary disease: a prospective study.
Kunisaki KM; Rice KL; Janoff EN; Rector TS; Niewoehner DE
Ther Adv Respir Dis; 2008 Apr; 2(2):55-64. PubMed ID: 19124359
[TBL] [Abstract][Full Text] [Related]
17. Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations.
Ferguson GT; Anzueto A; Fei R; Emmett A; Knobil K; Kalberg C
Respir Med; 2008 Aug; 102(8):1099-108. PubMed ID: 18614347
[TBL] [Abstract][Full Text] [Related]
18. Additional effects of pranlukast in salmeterol/fluticasone combination therapy for the asthmatic distal airway in a randomized crossover study.
Ohbayashi H; Shibata N; Hirose T; Adachi M
Pulm Pharmacol Ther; 2009 Dec; 22(6):574-9. PubMed ID: 19683591
[TBL] [Abstract][Full Text] [Related]
19. Effect of salmeterol/fluticasone propionate on airway inflammation in COPD: a randomised controlled trial.
Bourbeau J; Christodoulopoulos P; Maltais F; Yamauchi Y; Olivenstein R; Hamid Q
Thorax; 2007 Nov; 62(11):938-43. PubMed ID: 17557771
[TBL] [Abstract][Full Text] [Related]
20. Fluticasone propionate and salmeterol administered via Diskus compared with salmeterol or fluticasone propionate alone in patients suboptimally controlled with short-acting beta2-agonists.
Murray J; Rosenthal R; Somerville L; Blake K; House K; Baitinger L; VanderMeer A; Dorinsky P
Ann Allergy Asthma Immunol; 2004 Oct; 93(4):351-9. PubMed ID: 15521371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]